Biotech Values

[xrymd]

There are definitely protamine-related fatalities each year. In this litigious age, it's hard to defend the use of an inferior product that kills people assuming the alternative is not outrageously priced.

Protamine is also harder to use (it has to be accurately titrated) and heparin rebound can be a problem. So convenience too argues for the use of a superior replacement.

This point of reasoning seems similiar to recothrom (more theoretical than actual). The outcome will likely be the same unless they practically give it away.